EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)

Phase 1PST-611Neutral

AI Analysis

Summary

PulseSight Therapeutics will present Phase 1 clinical trial results of PST-611 for dry AMD/Geographic Atrophy at the 26th EURETINA Congress in Vienna on October 1-4, 2026.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.00

Phase 1dry AMDGeographic AtrophyEURETINAconference presentation

Read the original article

Published by GlobeNewswire Clinical Studies on September 16, 2026 7:00 AM

Read Original